Journal profile · BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ENGINEERING, BIOMEDICAL
Artificial Cells Nanomedicine and Biotechnology
ISSN 2169-1401 · eISSN 2169-141X · Informa Healthcare · UNITED STATES
Artificial Cells Nanomedicine and Biotechnology: CAS Zone 2 · Biology (2025 upgraded edition); impact factor 5.64; JCR Q1 (journal website); fully open access; APC about USD 2,990; median 126 days to acceptance (76 articles, last 24 months); acceptance rate 21% (journal website); 54 articles in 2025; indexed in SCIE and Scopus; flagged on an early-warning list or for an indexing change: check before submitting.
Scope
Aims, scope and focus
Artificial Cells Nanomedicine and Biotechnology is published by Informa Healthcare and is in Zone 2 of Biology in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Nanoparticle-Based Drug Delivery, Nanoparticles: synthesis and applications and Cancer-related molecular mechanisms research, together about 27% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Artificial Cells, Nanomedicine, and Biotechnology is an interdisciplinary journal, publishing high-quality open access research at the convergence of artificial cells, nanomedicine and health-related biotechnology. The journal places an emphasis on original research that demonstrates game-changing and disruptive technologies, new concepts and innovative experimental approaches. Articles featuring translational approaches such as clinical implementation may also be published in the journal. For work to be published it must be of significant interest to the artificial cell , nano health and biotechnology communities and must fall under one of the key subject areas listed below: Artificial cells: synthetic biology, synthetic organelles, build-a-cell artificial exosomes/extracellular vesicles synthetic genomics, self-assembly, origins of life application of artificial cells as: - biotherapeutics and immunotherapeutic (including stem cell therapy) - blood substitutes oxygen therapeutics - novel carriers for therapeutics (e.g. vaccines, drugs) bio-immunosorbents therapy Nanomedicine and biotechnology: bio/molecular nanosystems, nanoparticles including nanoscale bio/therapeutics and nano drug carriers, extracellular vesicles, smart and stimuli responsive nanobiosystems human physiology mimicking models, aka organ-on-chip nanotoxicity, nanotoxicology, biomedical sensors including sensor fusion mechanobiology, mechanopharmacology, mechanomedicine, precision nanomedicine nanofabrication, nanolithography and nanopatterning for biomedical applications single particle and single cell analysis, biomedical imaging, nanobiotechnology The convergence of information science, nano-scale science and molecular biology - nano-bio-info-cogno: bioconvergance and nano-bio-info-cogno network integrated nano-bio-technology platforms including bioinformatics, cognition and prediction The journal accepts original papers, reviews, method articles, data notes, registered reports, and editorials (by invitation only). Articles featuring translational approaches such as clinical implementation may also be published. Artificial Cells, Nanomedicine, and Biotechnology operates a single-anonymized peer review policy. Read the Instructions for Authors.
From the journal's Aims & Scope
Research area (LetPub): BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ENGINEERING, BIOMEDICAL
Editor-in-chief RDK MisraPublisher website
Editorial board by country: none in mainland China; most named Australia 2, United Kingdom 1, Canada 1, Netherlands 1 (5 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Nanoparticle-Based Drug DeliveryMaterials Science12%
- Nanoparticles: synthesis and applicationsMaterials Science8%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology7%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics6.5%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology5.9%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology5.9%
- Graphene and Nanomaterials ApplicationsEngineering5.6%
- Circular RNAs in diseasesBiochemistry, Genetics and Molecular Biology4.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Biology Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Biology | Zone 2 |
| Minor | Biotechnology & Applied Microbiology | Zone 2 |
| Minor | Engineering, Biomedical | Zone 3 |
| Minor | Materials Science, Biomaterials | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Biology Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Biology | Zone 2 |
| Minor | Biotechnology & Applied Microbiology | Zone 2 |
| Minor | Engineering, Biomedical | Zone 3 |
| Minor | Materials Science, Biomaterials | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Biology Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Biology | Zone 3 |
| Minor | Biotechnology & Applied Microbiology | Zone 3 |
| Minor | Engineering, Biomedical | Zone 3 |
| Minor | Materials Science, Biomaterials | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q1 · best quartile · 2025
- CiteScore Q1 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusDOAJLetPub
Early warning / risk: CAS Early Warning Journal List: listed in the 2020 edition (high risk); not listed in the other 5 editions.LetPub
Indexing the journal's website claims
EI CompendexMEDLINEPubMedEmbasePublisher website
Other: Academic Search Complete, Biochemistry and Biophysics Citation Index, Biological Abstracts, Biomedical Reference Collection: Comprehensive, BIOSIS Full Coverage Shared, BIOSIS Previews, Biotechnology Abstracts, Biotechnology Citation Index, EMBIOLOGY, Journal Citation Reports/Science Edition, SciSearch, SIIC
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.64LetPub ·
- Impact factor (publisher) 2025
- 5.6Publisher website ·
- 5-year impact factor (publisher) 2025
- 4.3Publisher website ·
- CiteScore 2026-06
- 8.5LetPub ·
- CiteScore (publisher) 2025
- 8.5Publisher website ·
- SJR 2026-06
- 0.97LetPub ·
- SJR (publisher) 2025
- 0.97Publisher website ·
- SNIP 2026-06
- 0.94LetPub ·
- SNIP (publisher) 2025
- 0.94Publisher website ·
- h-index
- 35LetPub ·
- h-index
- 114OpenAlex ·
- i10-index
- 1,660OpenAlex ·
- 2-year mean citedness
- 4.77OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 99.25%LetPub ·
Volume
- Articles per year
- 35LetPub ·
- Downloads per year (publisher)
- 1,000,000Publisher website ·
Articles by year OpenAlex count · 2,306 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 50 | 50 | 33 |
| 2025 | 54 | 54 | 176 |
| 2024 | 43 | 43 | 492 |
| 2023 | 61 | 61 | 975 |
| 2022 | 55 | 55 | 531 |
| 2021 | 132 | 132 | 1,624 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
126 daysMedian, submission to acceptance · P25–P75 97 days – 223 days
- Acceptance to online
- median 15 days (76 articles)
- Submission to online
- median 141 days
- Sample
- 76 articles with submission and acceptance dates (110 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 20 weeksLetPub ·
- Acceptance rate (publisher)
- 21%Publisher website ·
- Submission to first decision
- 9 daysPublisher website ·
- First decision after review
- 61 daysPublisher website ·
- Acceptance to publication
- 17 daysPublisher website ·
- Submission to publication (journal-reported)
- about 20 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 2,875 / USD 2,990 / GBP 2,392 | Yes | CC BY, CC BY-NC | |
| OpenAlex | GBP 2,085 | — | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted6
- data notesThe journal accepts original papers, reviews, method articles, data notes, registered reports, and editorials (by invitation only).Length not stated
- editorialsThe journal accepts original papers, reviews, method articles, data notes, registered reports, and editorials (by invitation only).Length not stated
- method articlesThe journal accepts original papers, reviews, method articles, data notes, registered reports, and editorials (by invitation only).Length not stated
- original papersThe journal accepts original papers, reviews, method articles, data notes, registered reports, and editorials (by invitation only).Length not stated
- registered reportsThe journal accepts original papers, reviews, method articles, data notes, registered reports, and editorials (by invitation only).Length not stated
- reviewsThe journal accepts original papers, reviews, method articles, data notes, registered reports, and editorials (by invitation only).Length not stated
Policy excerpts from the journal's websiteOpen access, Peer review
- Open access Open access
open access journal and only publishes open access articles Model summary
Artificial Cells, Nanomedicine, and Biotechnology is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability and readership of your article Make an impact and reach n…
Source ↗Publisher website ·- Peer review
single-anonymized peer review policy Model summary
Artificial Cells, Nanomedicine, and Biotechnology operates a single-anonymized peer review policy.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Informa Healthcare
- Country or region
- UNITED STATES
- Language
- English
- ISSN
- 2169-1401
- Electronic ISSN
- 2169-141X
- Latest issue on the website
- Volume 54, Issue 1 (2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Artificial Cells Nanomedicine and Biotechnology
What CAS zone is Artificial Cells Nanomedicine and Biotechnology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Artificial Cells Nanomedicine and Biotechnology is in Zone 2 of Biology, and in Zone 2 of the minor category Biotechnology & Applied Microbiology / Engineering, Biomedical / Materials Science, Biomaterials. In the 2026 Xinrui edition it is in Zone 2 of Biology. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Artificial Cells Nanomedicine and Biotechnology?
The latest impact factor listed by LetPub is 5.64; CiteScore 8.5, h-index 114.
How long does peer review take at Artificial Cells Nanomedicine and Biotechnology?
Based on the dates recorded on 76 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 126 days (interquartile range 97–223 days); authors report an average review time of about 20 weeks; the journal's website gives an acceptance rate of 21%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Artificial Cells Nanomedicine and Biotechnology in?
The journal's website gives JCR Q1 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 2 of Biology.
Where are the editorial board members of Artificial Cells Nanomedicine and Biotechnology based?
Of the 5 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Australia (2), United Kingdom (1) and Canada (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Artificial Cells Nanomedicine and Biotechnology?
According to LetPub and DOAJ records, Artificial Cells Nanomedicine and Biotechnology is indexed in SCIE, Scopus and DOAJ. The journal's website also lists EI Compendex, MEDLINE, PubMed and Embase; that list has not been checked against each database.
Is Artificial Cells Nanomedicine and Biotechnology open access, and what is the APC?
Artificial Cells Nanomedicine and Biotechnology is a fully open-access journal. APC about USD 2,990.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .